Published in Nutr Metab (Lond) on April 07, 2005
Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis. J Bone Miner Res (2008) 2.40
Dietary approaches that delay age-related diseases. Clin Interv Aging (2006) 1.37
Is obesity in women protective against osteoporosis? Diabetes Metab Syndr Obes (2011) 1.09
Bone and fat relationships in postadolescent black females: a pQCT study. Osteoporos Int (2010) 1.04
Adherence to the 2006 American Heart Association Diet and Lifestyle Recommendations for cardiovascular disease risk reduction is associated with bone health in older Puerto Ricans. Am J Clin Nutr (2013) 0.91
Bone density and bone area in Canadian Aboriginal women: the First Nations Bone Health Study. Osteoporos Int (2006) 0.84
Genetic relationships between obesity and osteoporosis in LGXSM recombinant inbred mice. Genet Res (Camb) (2008) 0.82
Racial difference in the correlates of bone mineral content/density and age at peak among reproductive-aged women. Osteoporos Int (2009) 0.78
Osteosarcopenic obesity in women: impact, prevalence, and management challenges. Int J Womens Health (2017) 0.77
The Relationship Between Body Mass Index and Bone Mineral Density in Premenopausal and Postmenopausal North Indian Women. J Obstet Gynaecol India (2014) 0.77
Effects of obesity on bone mass and quality in ovariectomized female Zucker rats. J Obes (2014) 0.77
A biomechanical sorting of clinical risk factors affecting osteoporotic hip fracture. Osteoporos Int (2015) 0.77
Association between secreted phosphoprotein-1 (SPP1) polymorphisms and low bone mineral density in women. PLoS One (2014) 0.75
Diabetes and Obesity as Independent Risk Factors for Osteoporosis: Updated Results from the ROIS/EMEROS Registry in a Population of Five Thousand Post-Menopausal Women Living in a Region Characterized by Heavy Environmental Pressure. Int J Environ Res Public Health (2016) 0.75
The emerging role of bone marrow adipose tissue in bone health and dysfunction. J Mol Med (Berl) (2017) 0.75
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med (1993) 6.08
The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone (1995) 5.76
Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res (1997) 4.74
Effects of weight and body mass index on bone mineral density in men and women: the Framingham study. J Bone Miner Res (1993) 3.31
Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int (1999) 2.70
Decreased incidence of hip fracture in Hispanics, Asians, and blacks: California Hospital Discharge Data. Am J Public Health (1988) 2.30
Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res (1997) 2.11
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Obesity as a protective factor for postmenopausal osteoporosis. Int J Obes Relat Metab Disord (1996) 1.59
Osteoporosis and African-American women. Womens Health Issues (2000) 1.48
Epidemiology and impact of rheumatic disorders in the United States Hispanic population. Curr Opin Rheumatol (2001) 1.09
Osteoporosis and African American women. J Womens Health Gend Based Med (1999) 1.07
Vertebral postmenopausal bone loss is reduced in overweight women: a longitudinal study in 155 early postmenopausal women. J Clin Endocrinol Metab (1993) 1.03
Obesity and postmenopausal bone loss: the influence of obesity on vertebral density and bone turnover in postmenopausal women. Bone (1987) 0.97
The effect of obesity on postmenopausal bone loss and the risk of osteoporosis. Adv Nutr Res (1994) 0.90
Ethnic and genetic differences in susceptibility to osteoporotic fractures. Adv Nutr Res (1994) 0.88
Bone mass, bone metabolism, gonadal status and body mass index. Osteoporos Int (2002) 0.86
Epidemiology of osteoporosis: predicting who is at risk. Ann N Y Acad Sci (1990) 0.85
Bone turnover and body weight relationships differ in normal-weight compared with heavier postmenopausal women. Osteoporos Int (2003) 0.84
Protective effect of moderate overweight on bone density of the hip joint in elderly and old Austrians. Anthropol Anz (2002) 0.82
New guidelines for the prevention and treatment of osteoporosis. National Osteoporosis Foundation. Med Health R I (1999) 0.81
[Significance of body weight status for bone density in the elderly and very old]. Z Gerontol Geriatr (2001) 0.81
[Obesity and osteoporosis: effect of weight variation on bone mass]. Nutr Hosp (2002) 0.78
Study classifies low body mass index as risk factor for osteoporotic fracture among older U.S. women. J Ark Med Soc (1999) 0.78
[Relation between body mass index and bone mineral density in a sample population of Mexican women]. Ginecol Obstet Mex (1998) 0.78
Metformin: an update. Ann Intern Med (2002) 5.62
Sleep duration among black and white Americans: results of the National Health Interview Survey. J Natl Med Assoc (2008) 3.82
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.71
IL-10 regulates murine lupus. J Immunol (2002) 1.70
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine (2004) 1.64
Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract (2008) 1.62
The case for low carbohydrate diets in diabetes management. Nutr Metab (Lond) (2005) 1.61
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) (2005) 1.51
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) (2008) 1.44
Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med (2008) 1.38
CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.37
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2004) 1.22
Hypertension and obesity. Recent Prog Horm Res (2004) 1.20
The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol (2004) 1.16
Sleep duration and the risk of diabetes mellitus: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2010) 1.14
Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.12
Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. Antioxid Redox Signal (2007) 1.12
Heart disease in diabetic patients. Curr Diab Rep (2003) 1.09
Diabetes insipidus: diagnosis and treatment of a complex disease. Cleve Clin J Med (2006) 1.08
Primary epiploic appendagitis: diagnosis, management, and natural course of the disease. Mil Med (2003) 1.02
Antiepileptic drugs and bone metabolism. Nutr Metab (Lond) (2006) 1.01
Obesity is associated with increased parathyroid hormone levels independent of glomerular filtration rate in chronic kidney disease. Metabolism (2009) 1.00
Cardiovascular disease risk reduction with sleep apnea treatment. Expert Rev Cardiovasc Ther (2010) 0.99
Cardiometabolic syndrome: pathophysiology and treatment. Curr Hypertens Rep (2003) 0.98
Linking sleep duration and obesity among black and white US adults. Clin Pract (Lond) (2013) 0.96
Dysglycemia predicts cardiovascular and kidney disease in the Kidney Early Evaluation Program. J Clin Hypertens (Greenwich) (2010) 0.94
Obesity, Diabetes, the Cardiorenal Syndrome, and Risk for Cancer. Cardiorenal Med (2012) 0.94
Gender disparity in outcomes of care and management for diabetes and the metabolic syndrome. Curr Diab Rep (2006) 0.93
Diabetic Cardiovascular Disease Predicts Chronic Kidney Disease Awareness in the Kidney Early Evaluation Program. Cardiorenal Med (2011) 0.93
The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep (2010) 0.93
Sleep apnea and diabetes: insights into the emerging epidemic. Curr Diab Rep (2011) 0.92
Group visits in the management of diabetes and hypertension: effect on glycemic and blood pressure control. Curr Diab Rep (2009) 0.92
Hypertension in pregnancy. Curr Hypertens Rep (2005) 0.92
Update on the prevention of type 2 diabetes. Curr Diab Rep (2011) 0.92
Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep (2004) 0.90
Antihypertensive medications and their effects on lipid metabolism. Curr Diab Rep (2008) 0.88
Eosinophilia among returning travelers: a practical approach. Am J Trop Med Hyg (2008) 0.88
Sudden cardiac death in patients with diabetes. Curr Diab Rep (2004) 0.88
Prevention of type 2 diabetes. Curr Diab Rep (2003) 0.87
Effect of ethnicity on the progression of diabetic kidney disease independent of glycemic control. Am J Nephrol (2009) 0.85
Heart failure in diabetic patients: utility of beta-blockade. J Card Fail (2003) 0.85
The Association between Parathyroid Hormone Levels and the Cardiorenal Metabolic Syndrome in Non-Diabetic Chronic Kidney Disease. Cardiorenal Med (2011) 0.85
New-onset diabetes after hemodialysis initiation: impact on survival. Am J Nephrol (2010) 0.85
The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program. J Clin Endocrinol Metab (2012) 0.84
Pleiotropic effects of inhibitors of the RAAS in the diabetic population: above and beyond blood pressure lowering. Curr Diab Rep (2010) 0.84
Treatment of hypertension in metabolic syndrome: implications of recent clinical trials. Curr Diab Rep (2009) 0.83
Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management. Curr Hypertens Rep (2005) 0.83
Telephone-delivered behavioral intervention among blacks with sleep apnea and metabolic syndrome: study protocol for a randomized controlled trial. Trials (2014) 0.83
Hypertension in people with diabetes and the metabolic syndrome: pathophysiologic insights and therapeutic update. Curr Diab Rep (2007) 0.82
Review on "Atkins Diabetes Revolution: The Groundbreaking Approach to Preventing and Controlling Type 2 Diabetes" by Mary C. Vernon and Jacqueline A. Eberstein. Nutr Metab (Lond) (2004) 0.82
Ashwagandha root in the treatment of non-classical adrenal hyperplasia. BMJ Case Rep (2012) 0.82
Metformin-responsive classic salt-losing congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a case report. Endocr Pract (2008) 0.81
High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. J Cardiometab Syndr (2008) 0.81
Cardiometabolic syndrome and chronic kidney disease. Curr Diab Rep (2006) 0.81
Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management. Curr Diab Rep (2011) 0.80
Threshold insulin-pump interruption to reduce hypoglycemia. N Engl J Med (2013) 0.80
Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep (2007) 0.79
The effects of lowering nighttime and breakfast glucose levels with sensor-augmented pump therapy on hemoglobin A1c levels in type 1 diabetes. Diabetes Technol Ther (2014) 0.78
Cardiovascular risk reduction via increasing HDL cholesterol: the promise of the dal-OUTCOMES Trial. Curr Diab Rep (2011) 0.78
Prevention of type 2 DM: implications for adolescents and young adults. Pediatr Endocrinol Rev (2008) 0.78
Validation of a novel risk estimation tool for predicting low bone density in Caucasian and African American men veterans. J Clin Densitom (2007) 0.78
Prevention of type 2 diabetes: an update. Curr Diab Rep (2007) 0.77
High Prevalence of Hypertension and Other Cardiometabolic Risk Factors in US- and Caribbean-Born Blacks with Chest Pain Syndromes. Cardiorenal Med (2012) 0.77
Admission hyperglycemia and length of hospital stay in patients with diabetes and heart failure: a prospective cohort study. Congest Heart Fail (2008) 0.76
Challenges in the diagnosis and management of new-onset diabetes after transplantation. Curr Diab Rep (2005) 0.76
Telmisartan and cardioprotection. Vasc Health Risk Manag (2011) 0.76
Narrowed Aortoseptal Angle Is Related to Increased Central Blood Pressure and Aortic Pressure Wave Reflection. Cardiorenal Med (2012) 0.76
Uncovering glucose abnormalities in people with hepatitis C infection: should oral glucose tolerance test become a standard of care? Am J Gastroenterol (2008) 0.76
Hypertension management in the high cardiovascular risk population. Int J Hypertens (2013) 0.75
Hypertension after renal transplant. J Clin Hypertens (Greenwich) (2007) 0.75
Calcium channel blockers reduce risk of stroke in people with hypertension. Commentary. Evid Based Cardiovasc Med (2005) 0.75
ONTARGET: use of ramipril, telmisartan, or both in patients with high cardiovascular risks. Curr Diab Rep (2009) 0.75
What are the long-term cardiovascular effects of treatment with rosiglitazone? Curr Diab Rep (2008) 0.75
Statins and CVD prevention in the diabetic population: implications of the CARDS trial. Curr Diab Rep (2005) 0.75
1-α hydroxylation defect in postural orthostatic tachycardia syndrome: remission with calcitriol supplementation. BMJ Case Rep (2012) 0.75
When the heart and the mind collide: cardiovascular risk factors and antipsychotic use in the schizophrenic population. J Cardiometab Syndr (2009) 0.75
Visual vignette. Ascites due to hypothyroidism. Endocr Pract (2011) 0.75
Therapeutic interventions for hypertension in metabolic syndrome: a comprehensive approach. Expert Rev Cardiovasc Ther (2007) 0.75
Heart failure: metabolic derangements and therapeutic rationale. Expert Rev Cardiovasc Ther (2007) 0.75
The Diabetes Prevention Program. Curr Diab Rep (2003) 0.75
The DREAM trial and the prospect of diabetes prevention. Curr Diab Rep (2006) 0.75
Clinical trials report. Hypertensive diabetic patients: INVESTing in the prevention of cardiovascular disease. Curr Hypertens Rep (2005) 0.75
Gender disparities in the control of cardiovascular risk factors in people with diabetes. J Clin Hypertens (Greenwich) (2005) 0.75
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient. Curr Hypertens Rep (2004) 0.75
Bone mineral density in African–American women with symptomatic uterine leiomyoma. Womens Health (Lond Engl) (2010) 0.75
Hepatitis C and the risk of cardiovascular disease: an evolving epidemic? Expert Rev Cardiovasc Ther (2006) 0.75
Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial. J Cardiometab Syndr (2007) 0.75
Adding low-dose spironolactone to multidrug regimens for resistant hypertension. Curr Hypertens Rep (2004) 0.75
Cardiovascular disease in diabetes and the cardiometabolic syndrome: focus on minority women. Curr Diab Rep (2005) 0.75
Posttransplant diabetes and hypertension: pathophysiologic insights and therapeutic rationale. Curr Diab Rep (2008) 0.75
Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial. Curr Diab Rep (2010) 0.75